DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21107/S-024

SUPPLEMENT APPROVAL

Prometheus Laboratories, Inc.
Attention: John Baiano, Ph.D.
Senior Director, Regulatory Affairs and CMC
9410 Carroll Park Drive
San Diego, California 92121

Dear Dr. Baiano:

Please refer to your Supplemental New Drug Application (sNDA) dated February 11, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lotronex (alosetron hydrochloride) tablets, 1 mg and 0.5 mg.

We acknowledge receipt of your amendments dated April 4, 2014 and April 18, 2014.

This "Prior Approval" supplemental new drug application provides for proposed modifications to the approved Lotronex (alosetron hydrochloride) REMS.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Lotronex (alosetron hydrochloride) was originally approved on September 2, 2010. The REMS consists of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of the following revisions to the PPL Prescriber Enrollment Form:

- Requesting the NPI number rather than the DEA number
- Prompting for complete address information (i.e., street, city, state, and zip code)
- Adding a new facsimile number

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Your proposed modified REMS, submitted on April 18, 2014, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on September 2, 2010.

There are no changes to the REMS assessment plan described in our September 2, 2010 letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

NDA 21107 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 21107 REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 21107
PROPOSED REMS MODIFICATION

NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 21107
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CDR Anissa Davis-Williams, Senior Regulatory Project Manager, at (301) 796-5016.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.P.H., M.D.
Deputy Director, Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: REMS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
05/08/2014